Table 3.
Patients With Myelofibrosis Who Responded to Lenalidomide and Prednisone Therapy
| No. | Age (years) | Prior Myelofibrosis-Directed Therapy | Spleen (cm) | WBC (× 109/L) | Hemoglobin (× 109/L) | Platelets (× 109/L) | JAK2V617F allele (%) | No. of Cycles to Response | Response | Response Duration (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 73 | Darbepoietin | 10 | 8.4 | 7.8 | 202 | 45.7 | 7 | CI (hemoglobin, spleen) | 14+ |
| 2 | 55 | PEG-IFNα2b | 9 | 4.4 | 9.5 | 232 | 51.8 | 3 | CI (hemoglobin, spleen) | 24+ |
| 3 | 45 | IFNα | 11 | 5 | 10.6 | 181 | 0 | 8 | PR | 18+ |
| 4 | 52 | None | 15 | 12.5 | 11.6 | 156 | 81.2 | 6 | CI (spleen) | 20+ |
| 5 | 80 | None | 10 | 3 | 9.1 | 95 | 0 | 3 | PR | 21+ |
| 6 | 76 | None | 15 | 31.5 | 17.3 | 167 | 89 | 3 | CI (spleen) | 20+ |
| 7 | 71 | Hydroxyurea, erythropoietin | 12 | 18.6 | 12.2 | 358 | 0 | 2 | CI (spleen) | 19+ |
| 8 | 59 | None | 22 | 22.3 | 10.3 | 704 | 86.8 | 2 | CI (spleen) | 18+ |
| 9 | 69 | Hydroxyurea, darbepoietin, 5-azacitidine | 10 | 35.3 | 8.2 | 93 | 89.15 | 2 | CI (spleen) | 3.5 |
| 10 | 72 | Thalidomide + PRD, darbepoietin | 0 | 7.2 | 8.1 | 309 | 0 | 3 | PR | 6 |
| 11 | 68 | None | 0 | 5.4 | 9.1 | 440 | 28.35 | 4 | CI (hemoglobin) | 12+ |
| 12 | 56 | Hydroxyurea, darbepoietin | 20 | 17.4 | 9.7 | 90 | 89.6 | 1 | CI (hemoglobin, spleen) | 18+ |
Abbreviations: WBC: white blood cell; CI, clinical improvement; PEG-IFNα2b: pegylated interferon alpha 2b; PR, partial response; NA, not available; PRD, prednisone.